---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-069810"
form_type: "8-K"
ticker: "RNAZ"
cik: "0001829635"
company_name: "Transcode Therapeutics, Inc."
filed_at: "2026-06-03T12:08:44+00:00"
generated_at: "2026-06-03T12:10:11.277547+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# TransCode Phase 1a TTX-MC138 trial meets safety endpoint; 64% stable disease at 6 months

## Summary
- 16 patients received 86 doses; median treatment 11.3 weeks (range 4-52.4 weeks).
- No dose-limiting toxicities; recommended Phase 2a dose set at 4.8 mg/kg.
- 9 of 14 evaluable patients (64%) achieved stable disease lasting ≥6 months.
- Three patients remain on study (at 21, 16, and 14 cycles); one thyroid cancer patient had dramatic thyroglobulin drop.
- Phase 2a trial initiated in ctDNA-positive colorectal cancer after curative-intent therapy.

## SEC filing metadata
- accession: 0001104659-26-069810
- form_type: 8-K
- ticker: RNAZ
- cik: 0001829635
- company_name: Transcode Therapeutics, Inc.
- filed_at: 2026-06-03T12:08:44+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829635/000110465926069810/0001104659-26-069810-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829635/000110465926069810/tm2616719d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-069810
- JSON: https://secwatch.observer/filing/0001104659-26-069810.json
- Plain text: https://secwatch.observer/filing/0001104659-26-069810.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.